Treatment of Chronic Migraine: A 3‐Month Comparator Study of Naproxen Sodium vs<scp>SumaRT</scp>/<scp>N</scp>ap

Cady, Roger; Nett, Robert; Dexter, Kent; Freitag, Fred; Beach, M.E.; Manley, Heather R.

doi:10.1111/head.12210

Cited by 17 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The result of this study showed that the addition of propranolol long-acting (240 mg daily) to topiramate 50–100 mg per day does not add benefit when CM is inadequately controlled with topiramate alone. In another small pilot trial of 28 subjects, the combination of sumatriptan 85 mg plus naproxen 500 mg in a combination tablet did not reduce headache frequency over a 3-month period 60. Nevertheless, further clinical trials are needed to search for better combination therapies for CM patients.…”

Section: Management Of Chronic Migrainementioning

confidence: 97%

Tackling chronic migraine: current perspectives

Carod-Artal¹

2014

JPR

View full text Add to dashboard Cite

In the last decade, several diagnostic criteria and definitions have been proposed for chronic migraine (CM). The third edition of the International Classification of Headache Disorders–3 beta, published in 2013, has revised CM diagnostic criteria. CM is defined as “headache occurring on 15 or more days per month for more than 3 months, which has the features of migraine headache on at least 8 days per month.” Patients who meet the criteria for CM and for medication-overuse headache should be given both diagnoses. Worldwide, CM prevalence ranges 1%–3%, and its incidence has been estimated to be 2.5% per year. CM is associated with disability and poor quality of life. Modifiable risk factors include (among others): migraine progression (defined as an increase in frequency and severity of migraine attacks); medication and caffeine overuse; obesity; stressful life events; and snoring. CM patients have a significantly higher frequency of some comorbid conditions, including chronic pain, psychiatric disorders, respiratory illness, and some vascular risk factors. Management includes identification and control of comorbidities and risk factors that predispose to CM; treatment and prevention for medication overuse; early treatment for migraine attacks; and an adequate preventive therapy for CM. Several randomized controlled clinical trials have shown the efficacy of topiramate, amitriptyline, onabotulinumtoxinA, and cognitive-behavioral therapy in CM.

show abstract

Section: Management Of Chronic Migrainementioning

confidence: 97%

Tackling chronic migraine: current perspectives

Carod-Artal¹

2014

JPR

View full text Add to dashboard Cite

show abstract

“…77 Subjects received daily study medication for 1 month, and then used the same study drug as acute treatment for the subsequent 2 months. At the end of the first month, there was a 60% reduction in headache days for naproxen compared with a 24% reduction for sumatriptan/naproxen.…”

Section: Naproxen Vs Sumatriptan/naproxenmentioning

confidence: 99%

Chronic Migraine

Cady

Durham

2015

Headache and Migraine Biology and Management

View full text Add to dashboard Cite

“…High‐quality data on this topic are even scanter in children and adolescents. Some adult data suggest frequent NSAID use is associated with lower headache frequency over time . We need better data to determine whether clinicians should continue to restrict acute medication use or allow patients to treat at the frequency their migraine symptoms dictate.…”

Section: Introductionmentioning

confidence: 99%